Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism

被引：60

作者：

Tang, Jun ^{[1
,2
]}

Ye, Lifang ^{[1
,2
]}

Yan, Qiqi ^{[1
,2
]}

Zhang, Xin ^{[1
,2
]}

Wang, Lihong ^{[1
,2
]}

机构：

[1] Zhejiang Chinese Med Univ, Clin Med Coll 2, Hangzhou, Peoples R China

[2] Hangzhou Med Coll, Zhejiang Prov Peoples Hosp, Dept Cardiovasc Med, Peoples Hosp, Hangzhou, Peoples R China

来源：

FRONTIERS IN PHARMACOLOGY | 2022年 / 13卷

基金：

中国国家自然科学基金;

关键词：

sodium-glucose cotransporter 2 inhibitor; heart failure; diuretic effect; natriuresis; glycosuria; HEART-FAILURE; DIABETES-MELLITUS; SGLT2; INHIBITORS; BLOOD-PRESSURE; DAPAGLIFLOZIN TREATMENT; ARTERIAL STIFFNESS; KIDNEY-DISEASE; DOUBLE-BLIND; WEIGHT-LOSS; FAT MASS;

D O I：

10.3389/fphar.2022.800490

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Sodium-glucose cotransporter 2 (SGLT2) inhibitors exert hypoglycemic and diuretic effects by inhibiting the absorption of sodium and glucose from the proximal tubule. Currently available data indicate that SGLT2 inhibitors transiently enhance urinary sodium excretion and urinary volume. When combined with loop diuretics, SGLT2 inhibitors exert a synergistic natriuretic effect. The favorable diuretic profile of SGLT2 inhibitors may confer benefits to volume management in patients with heart failure but this natriuretic effect may not be the dominant mechanism for the superior long-term outcomes observed with these agents in patients with heart failure. The first part of this review explores the causes of transient natriuresis and the diuretic mechanisms of SGLT2 inhibitors. The second part provides an overview of the synergistic effects of combining SGLT2 inhibitors with loop diuretics, and the third part summarizes the mechanisms of cardiovascular protection associated with the diuretic effects of SGLT2 inhibitors.

引用

页数：12

共 122 条

[1] Diuretic Effects of Sodium Glucose Cotransporter 2 Inhibitors and Their Influence on the Renin-Angiotensin System [J].

Ansary, Tuba M. ;

Nakano, Daisuke ;

Nishiyama, Akira .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (03)

[2] Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis [J].

Baker, William L. ;

Smyth, Lindsay R. ;

Riche, Daniel M. ;

Bourret, Emily M. ;

Chamberlin, Kevin W. ;

White, William B. .

JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION, 2014, 8 (04) :262-275

[3] Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications [J].

Bakris, George L. ;

Fonseca, Vivian A. ;

Sharma, Kumar ;

Wright, Ernest M. .

KIDNEY INTERNATIONAL, 2009, 75 (12) :1272-1277

[4] Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial [J].

Barnett, Anthony H. ;

Mithal, Ambrish ;

Manassie, Jenny ;

Jones, Russell ;

Rattunde, Henning ;

Woerle, Hans J. ;

Broedl, Uli C. .

LANCET DIABETES & ENDOCRINOLOGY, 2014, 2 (05) :369-384

[5] Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure [J].

Bhatt, Deepak L. ;

Szarek, Michael ;

Steg, P. Gabriel ;

Cannon, Christopher P. ;

Leiter, Lawrence A. ;

McGuire, Darren K. ;

Lewis, Julia B. ;

Riddle, Matthew C. ;

Voors, Adriaan A. ;

Metra, Marco ;

Lund, Lars H. ;

Komajda, Michel ;

Testani, Jeffrey M. ;

Wilcox, Christopher S. ;

Ponikowski, Piotr ;

Lopes, Renato D. ;

Verma, Subodh ;

Lapuerta, Pablo ;

Pitt, Bertram .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (02) :117-128

[6] Canagliflozin triggers the FGF23/1,25-dihydroxyvitamin D/PTH axis in healthy volunteers in a randomized crossover study [J].

Blau, Jenny E. ;

Bauman, Viviana ;

Conway, Ellen M. ;

Piaggi, Paolo ;

Walter, Mary F. ;

Wright, Elizabeth C. ;

Bernstein, Shanna ;

Courville, Amber B. ;

Collins, Michael T. ;

Rother, Kristina I. ;

Taylor, Simeon I. .

JCI INSIGHT, 2018, 3 (08)

[7] Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin [J].

Bolinder, Jan ;

Ljunggren, Osten ;

Kullberg, Joel ;

Johansson, Lars ;

Wilding, John ;

Langkilde, Anna Maria ;

Sugg, Jennifer ;

Parikh, Shamik .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (03) :1020-1031

[8] Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure [J].

Boorsma, Eva M. ;

Beusekamp, Joost C. ;

ter Maaten, Jozine M. ;

Figarska, Sylwia M. ;

Danser, A. H. Jan ;

van Veldhuisen, Dirk J. ;

van Der Meer, Peter ;

Heerspink, Hiddo J. L. ;

Damman, Kevin ;

Voors, Adriaan A. .

EUROPEAN JOURNAL OF HEART FAILURE, 2021, 23 (01) :68-78

[9] Empagliflozin Inhibits Proximal Tubule NHE3 Activity, Preserves GFR, and Restores Euvolemia in Nondiabetic Rats with Induced Heart Failure [J].

Borges-Junior, Avio A. ;

dos Santos, Danubia Silva ;

Benetti, Acaris ;

Polidoro, Juliano Z. ;

Wisnivesky, Aline C. T. ;

Crajoinas, Renato O. ;

Antonio, Ednei L. ;

Jensen, Leonardo ;

Caramelli, Bruno ;

Malnic, Gerhard ;

Tucci, Paulo J. ;

Girardi, Adriana C. C. .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (07) :1616-1629

[10] Outcomes Associated With a Strategy of Adjuvant Metolazone or High-Dose Loop Diuretics in Acute Decompensated Heart Failure: A Propensity Analysis [J].

Brisco-Bacik, Meredith A. ;

ter Maaten, Jozine M. ;

Houser, Steven R. ;

Vedage, Natasha A. ;

Rao, Veena ;

Ahmad, Tariq ;

Wilson, F. Perry ;

Testani, Jeffrey M. .

JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2018, 7 (18)

← 1 2 3 4 5 6 7 8 9 10 →